Ancilia Biosciences

(Acquired by Virgin Pulse for $6M*)  

Overview

Computational bio-platform that engineers phage-resistant bacterial therapeutics utilizing CRISPR to treat microbiome-linked diseases, including inflammatory bowel disease and immunotherapy-associated colitis. Proprietary platform that allows them to identify virulent phage populations present in the gut.

Category

Biotech

Sub-Category

Microbiome

Round

Seed

Notable Investors

NEU FUND, Deep Science Ventures

Initial Investment

December 2020

website

×

Alto Neuroscience

(Acquired by Virgin Pulse for $6M*)  

Overview

Precision medicine for the brain is here. Alto is pioneering an approach to psychiatric drug development which matches the right patient with the right Alto drug based on AI-derived brain biomarkers.

Category

Biotech

Sub-Category

AI-based Drug Discovery

Round

Series B

Notable Investors

Apeiron Investment Group, Presight Capital, What if Ventures

Initial Investment

March 2022

website

×

Aspen Neuroscience

(Acquired by Virgin Pulse for $6M*)  

Overview

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson’s disease and extending across the brain and affected organs.

Category

Biotech

Sub-Category

Cell Therapy

Round

Series B

Notable Investors

Google Ventures, Arch Ventures, Domain Associates, OrbiMed, Section 32

Initial Investment

April 2022

website

×

Blue Mesa Health

(Acquired by Virgin Pulse for $6M*)  

Overview

Developer of diabetes prevention digital platform designed to prevent or delay Type 2 Diabetes. The company's application offers wireless scale and activity tracker for monitoring progress, enabling users to lose approximately 5-7% of their body weight and reduce type2 diabetes risk by 58%.

Category

Digital Health

Sub-Category

Initial Investment

February 2018

website

×

BioROSA Technologies

(Acquired by Virgin Pulse for $6M*)  

Overview

BioROSA focuses on Autism Spectrum Disorders(ASD). BioROSA leverages machine learning for biologically-based screening, diagnosis, and therapeutic trials to assess pharmacodynamics, patient stratification, and companion diagnostic, enabling doctors to get the tools they need to help in earlier detection, diagnosis, and timely treatment.

Category

Diagnostics

Sub-Category

AI-enabled Diagnostics

Round

Seed

Notable Investors

Hibiscus Capital Management, Digital Dx Ventures,
OCA Ventures, SOSV

Initial Investment

July  2021

website

×

Bionaut Labs

(Acquired by Virgin Pulse for $6M*)  

Overview

Bionaut is creating a new treatment modality that uses microscale robots to deliver biologics or small molecule therapies locally to targeted disease areas to help patients suffering from severe brain disorders.

Category

MedTech (Robotics & Drones)

Sub-Category

Drug Delivery

Round

Series B

Notable Investors

Khosla Ventures, Upfront Ventures, Bold Capital Partners, Edge of Chaos, Kapor Capital

Initial Investment

January 2022

website

×

Circularis Biotechnologies

(Acquired by Ginko for $56M*)

Overview

Using circular RNA, Circularis enables customers to optimize control of any gene in any species or any cell type. The company’s proprietary platform is the only technology for discovering, isolating, measuring, and enhancing all active promoters in a DNA sequence in a single reaction.

Category

Life Sciences

Sub-Category

Synthetic Biology

Round

Seed, Bridge

Notable Investors

KdT Ventures, SOSV, Alix, CANTOS Ventures

Initial Investment

August 2020

website

×

CrowdMed

(Acquired by Virgin Pulse for $6M*)  

Overview

CrowdMed is the developer of an online medical community platform intended to provide patients with a clear path towards their diagnosis and cure. The company's platform provides a collaborative approach for solving complex medical cases, enabling them to explore all possible medical diagnosis with reduced costs.

Category

Digital Health

Sub-Category

Online Diagnostics

Round

Seed

Notable Investors

Khosla Ventures, NEA, Andreessen Horowitz, greylock partners

Initial Investment

February 2017

website

×

Contraline

(Acquired by Virgin Pulse for $6M*)  

Overview

Contraline is developing ADAM™, the world's first injectable hydrogel designed to provide men with long-lasting contraception. It's like the IUD, for men. ADAM is a non-hormonal, non-surgical and reversible polymer hydrogel implanted into the vas deferens, acting as a semipermeable membrane and blocking sperm while allowing fluids through.

Category

MedTech

Sub-Category

Reproductive Health

Round

Seed, Series A

Notable Investors

Google Ventures, Founders Fund, Gaingels, Abstract Ventures

Initial Investment

April 2020

website

×

Echo Laboratories

(Acquired by Cellinkfor $110M*)

Overview

Echo is a hybrid microscopy developer designed for biological research and pathologies. The company's products provide features such as inverted images, cell counting, phase contrast, bright field and fluorescence, enabling customers to have accurate images at a low cost.

Category

Life Sciences

Sub-Category

Tools & Equipment

Round

Seed, Bridge, Series A

Notable Investors

Dolby Family, Tech Coast Angels

Initial Investment

October 2016

website

×

EnClear Therapies

(Acquired by Virgin Pulse for $6M*)  

Overview

Enclearis building an Integrated Neuro technology Business using its CSF health platform to provide precision dosing of CNS based therapeutics. They are launching into neuro oncology and plan to expand into neurodegenerative, lysosomal storage & autoimmune diseases.

Category

MedTech

Sub-Category

Drug Delivery

Round

Seed, Bridge

Notable Investors

Theil, Dolby Family Ventures, Presight Capital,
AMGEN Ventures, 20/20 Health care partners

Initial Investment

March 2019

website

×

Excision BioTherapeutics

(Acquired by Virgin Pulse for $6M*)  

Overview

Developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients, starting with HIV. The company's therapies eradicate or disrupt viral genes in patients into safe and efficacious medicines, enabling hospitals to treat diseases caused by viral infections effectively.

Category

Biotech

Sub-Category

Genetic Editing Medicine

Round

Seed

Notable Investors

Cota Capital, Gaingels, Greatpoint, Artis Ventures,
Abstract Ventures

Initial Investment

March 2020

website

×

Elucid

(Acquired by Virgin Pulse for $6M*)  

Overview

Elucid is leveraging machine intelligence to improve the effectiveness of vascular diagnostic imaging. Its ground breaking product, ElucidVivo, is the first FDA-cleared &CE-marked, histology-validated, non-invasive image analysis software providing multi-dimensional visualization to inform patients of the risk of heart attack or stroke.

Category

Diagnostics

Sub-Category

Imaging

Round

Seed

Notable Investors

Global Health Impact Network, MedTex, NIH

Initial Investment

March 2021

website

×

Enveda Biosciences

(Acquired by Virgin Pulse for $6M*)  

Overview

Enveda constructs and decodes an integrated dataset from medicinal plants to inspire new medicines. The company's platform systematizes the discovery of drugs like aspirin, auinine, metformin, and CBD by intelligently probing the "dark" bio-chemical space of medicinal plants, thereby enabling the healthcare industry to discover new medicines.

Category

Biotech

Sub-Category

AI-based Drug Discovery

Round

Series A, Series B

Notable Investors

Lux, Village Global, Catalio, Humming Bird, True Ventures,
Life Force Capital

Initial Investment

June 2021

website

×

Eigen Therapeutics

(Acquired by Virgin Pulse for $6M*)  

Overview

Eigen is building biological, software, and hardware tools to search the vast combinatorial landscape to discover synergistic therapies that improve efficacy while reducing toxicity of small molecule therapies and immunotherapies.

Category

Biotech

Sub-Category

AI-based Drug Discovery

Round

Seed

Notable Investors

First Round, Builders VC

Initial Investment

February 2022

website

×

Foresight Mental Health

(Acquired by Virgin Pulse for $6M*)  

Overview

Foresight Mental Health is transforming mental healthcare by leveraging cutting-edge science and technology while remaining affordable and accessible. Care at Foresight begins with building a member profile based on the patient's genetic profile, comprehensive symptom profile, brain-chemical balance estimates, mental health history, family history, lifestyle, and many other factors

Category

Healthcare Services

Sub-Category

Mental Health

Round

Seed, Bridge, Series C

Notable Investors

Sequoia, Polaris Partners, Jaz Ventures Partners

Initial Investment

February 2020

website

×

GigaMune

(Acquired by Virgin Pulse for $6M*)  

Overview

GigaMune is developing novel technology for in vivo targeted gene delivery of T cell receptors and chimeric antigen receptors to treat serious diseases such as cancer and autoimmune diseases. GigaMune’s vision is to bring gene therapy into mainstream medicine through in vivo delivery of any gene to any cell in any tissue location.

Category

Biotech

Sub-Category

Cell Therapy

Round

Seed

Notable Investors

Sequoia Capital Scout Program, Boost VC

Initial Investment

November 2022

website

×

HepaTx Corporation

(Acquired by Virgin Pulse for $6M*)  

Overview

HepaTx develops stem cell-based therapies to replace liver transplants. Its therapies are based on the principles of regenerative medicine, which allow the patient's body to actively repair damaged tissues and organs, enabling physicians to easily help previously untreatable patients in a cost-effective way.

Category

Biotech

Sub-Category

Cell Therapy

Round

Seed

Notable Investors

StartX, Grey Sky, Combinator, Sand Hill Angels

Initial Investment

May 2021

website

×

Intelligent Implants

(Acquired by Virgin Pulse for $6M*)  

Overview

Intelligent Implants develops electrotherapeutic devices for disease treatment and recovery in bone and other tissues. It offers an implantable medical device that can accelerate and adjust bone growth, enabling healthcare providers to use electro-therapeutics to control and monitor patient bone conditions and make faster decisions.

Category

MedTech

Sub-Category

Spinal Fusion

Round

Seed. Bridge

Initial Investment

September  2019

website

×

IVIVA Medical

(Acquired by Virgin Pulse for $6M*)  

Overview

IVIVA develops autologous tissue constructs for end-stage renal diseases. The company is using tissue engineering, 3D additive manufacturing, and stem cell biology to develop bioartificial platforms for regenerative medicine to end donor organ shortage, enabling medical communities to optimally combat end-state kidney disease

Category

Biotech

Sub-Category

Organ Replacement

Round

Seed

Notable Investors

Bold Capital Partners, Prime Movers Lab,
Department of Defense, Johnson & Johnson

Initial Investment

March 2021

website

×

Juno Diagnostics

(Acquired by Virgin Pulse for $6M*)  

Overview

Juno offers in-home, cell-free DNA-based noninvasive prenatal tests that amplify sample collection and access to high-quality test results without the high cost, long lead times, and phlebotomy requirements of traditional NIPT, enabling women and their physicians with vital health information.

Category

Diagnostics

Sub-Category

Prenatal Testing

Round

Series A

Notable Investors

Perceptive Advisors, Charge, Zapital, Colle Capital

Initial Investment

May 2021

website

×

JelikaLite

(Acquired by Virgin Pulse for $6M*)  

Overview

JelikaLite developed Cognilum, a wearable headset that harnesses the power of Photobiomodulation to reduce symptoms of autism in children, by improving language skills, and responsiveness. It combines non-invasive brain stimulation with infrared light, sensors and an AI personalization platform.

Category

Medtech

Sub-Category

Autism Care

Round

Seed

Notable Investors

the brain foundation, New York Ventures

Initial Investment

December 2022

website

×

Leucadia Therapeutics

(Acquired by Virgin Pulse for $6M*)  

Overview

Leucadia develops a medical technology platform designed to advanced treatments for Alzheimer's disease. Its platform restores CSF flow across the cribriform plate, improving the clearance of toxic metabolites from the earliest regions of the brain to be affected by Alzheimer's disease, enabling precise and effective Alzheimer treatments.

Category

Diagnostics

Sub-Category

Alzheimer’s

Round

Seed

Notable Investors

Wasabi Ventures Partners, Methuselah Fund,
Methuselah Foundation

Initial Investment

June 2019

website

×

Ligandal

(Acquired by Virgin Pulse for $6M*)  

Overview

Ligandal develops nanomedicine therapies as gene editing tools with non-viral nano-carriers to treat gene-related diseases. Its therapies include peptide-based technologies for high-precision gene therapy, gene editing, regenerative medicine, immunotherapy, advance dantidote-vaccine technology genetic materials.

Category

Biotech

Sub-Category

Genetic Engineering

Round

Seed, Bridge

Notable Investors

Social Capital, Hemisphere Ventures, Techammer

Initial Investment

October 2017

website

×

Modulo Bio

(Acquired by Virgin Pulse for $6M*)  

Overview

Reprogramming the brain’s immune system to protect neurons from neurodegenerative diseases.  Modulo is reprogramming microglia into a neuroprotective state that extends the life of neurons and slows or reverses disease progression. Modulo has built an iterative machine learning-guided cellular model of neuro immune disorders.

Category

Biotech

Sub-Category

AI-enabled Drug Discovery

Round

Seed+

Notable Investors

initialized, builders, Refactor

Initial Investment

March 2023

website

×

Notable Labs

(Acquired by Virgin Pulse for $6M*)  

Overview

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment.

Category

Biotech

Sub-Category

Precision Medicine

Initial Investment

October 2016

website

×

NutriSense

(Acquired by Virgin Pulse for $6M*)  

Overview

NutriSense is a monitoring device and mobile application intended to personalize nutrition. The company provides continuous glucose monitoring devices on a monthly basis, meal, activity, and fasting tracking, enabling subscribers to understand their metabolism and take control of their health.

Category

Digital Health

Sub-Category

Wearables & Quantified Self

Round

Seed, Series A

Notable Investors

1315 Capital, Launch, techstars

Initial Investment

September 2021

website

×

OccamzRazor

(Acquired by Virgin Pulse for $6M*)  

Overview

OccamzRazor is an AI-driven neuro science therapeutics platform for Parkinson's Disease. It analyzes a variety of biomedical data sets, constructing knowledge graph representing all known information about Parkinson's disease, enabling healthcare professionals to drive downstream therapeutic insight and strategic drug development.

Category

Biotech

Sub-Category

AI-enabled Drug Discovery

Round

Seed

Notable Investors

Dreamers VC, LanxCapital, Techammer

Initial Investment

October 2018

website

×

Ombre

(Acquired by Virgin Pulse for $6M*)  

Overview

The world's first Gut Health program that includes both Personalized Probiotics & Microbiome Testing. Your gut is the center of your health, so Ombre created a personalized probiotic adapted from a DNA sample to target your root cause. Strain-specific probiotic subscription clinically supported to address your symptoms.

Category

Diagnostics

Sub-Category

Microbiome

Round

Seed. Bridge

Notable Investors

Unilever Ventures, Pivot North Capital

Initial Investment

November 2019

website

×

Ochre Bio

(Acquired by Virgin Pulse for $6M*)  

Overview

Ochre Bio develops RNA medicines for chronic liver diseases by rejuvenating donors' livers before transplant. The company uncovers new biological pathways with advanced 'deep phenotyping', and then studies medicines in human livers kept alive on machines to successfully improve patient lives.

Category

Biotech

Sub-Category

Organ Replacement

Round

Series A

Notable Investors

Khosla Ventures, Apollo Health Ventures, Life Force Capital

Initial Investment

November 2021

website

×

Octagon Therapeutics

(Acquired by Virgin Pulse for $6M*)  

Overview

Octagon develops targeted immunomodulator medicines. Octagon’s medicines are developed recognizing the immune cells that cause these disorders are metabolically distinct from healthy immune cells, enabling patients to avoid chronic immunosuppression by selectively targeting dysregulated immune cells.

Category

Biotech

Sub-Category

Drug Discovery (autoimmune)

Round

Seed, Bridge

Notable Investors

Biorock Ventures, Walnut Ventures, Kyto, Sand Hill Angels, Keiretsu Forum

Initial Investment

October 2020

website

×

Octant Bio

(Acquired by Virgin Pulse for $6M*)  

Overview

Octant’s platform uses synthetic biology, high throughput multiplexed assays, synthetic chemistry, and computation to engineer and interrogate drugs, proteins, and signaling path ways at unprecedented scales.

Category

Biotech

Sub-Category

AI-enabled Drug Discovery

Round

Series B

Notable Investors

andreessen horowitz, 8vc, LUX, Refactor, SVAngel

Initial Investment

February 2022

website

×

Pragma Bio

(Acquired by Virgin Pulse for $6M*)  

Overview

Pragma Bio transforms cancer therapy through the microbiome. It uses proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and novel therapeutics for the most challenging immunologic disorders, enabling clinicians to better serve their patients.

Category

Biotech

Sub-Category

AI-enabled Drug Discovery

Round

Seed, Series A

Notable Investors

Illumina Accelerator, Merck Global Health Innovation, Viking, Plug and Play

Initial Investment

June 2020

website

×

Repair Biotechnologies  

(Acquired by Virgin Pulse for $6M*)  

Overview

Preclinical-stage biotech company developing several first-in-class therapies based on innovative Cholesterol Degrading Platform, a safe and well tolerated approach to treating the cause of medical conditions that arise due to localized accumulations of excess cholesterol.

Category

Biotech

Sub-Category

Gene Therapy

Round

Seed

Notable Investors

Emerging Longevity Ventures,, 100 Capital, Juvenescence, Methuselah Fund

Initial Investment

October 2020

website

×

RockStep Solutions

(Acquired by Virgin Pulse for $6M*)  

Overview

RockStep Solutions is revolutionizing drug discovery with a cloud informatics platform for managing data and operations. RockStep's flagship product, Climb, solves the problem of data chaos and operational inefficiencies which is causing a huge drop in ROI for drug research.

Category

Life Science

Sub-Category

Round

Seed

Notable Investors

Maine Angels, mti, NIH, nex3

Initial Investment

April 2020

website

×

Suggestic

(Acquired by Virgin Pulse for $6M*)  

Overview

Suggestic is a personalized nutrition platform designed to facilitate precision eating among users. Its AI-based nutrition coaching platform offers personalized diet plans based on users' goals, dietary preferences and restrictions, enabling individuals to lose weight, increase vitality and prevent or even reverse chronic diseases.

Category

Digital Health

Sub-Category

AI-based Nutrition & Wellness

Initial Investment

October 2019

website

×

Volumetric

(Acquired by 3D Systems for $400M*)

Overview

Volumetric is developing technology for 3D bioprinting of human tissue and organs using 3Dstereolithography, representing a 50x-100x leap in speed and 10x leap in resolution compared to legacy bioprinting methods. They have already produced the world’s most complex 3D-printed object ever – a human lung scaffold - which has demonstrated gas exchange in animal models

Category

Biotech

Sub-Category

3D Bioprinting

Round

Seed

Notable Investors

TMC, Combinator

Initial Investment

July 2020

website

×

Volumetric

(Acquired by 3D Systems for $400M*)

Acquired by

Overview

Volumetric is developing technology for 3D bioprinting of human tissue and organs using 3Dstereolithography, representing a 50x-100x leap in speed and 10x leap in resolution compared to legacy bioprinting methods. They have already produced the world’s most complex 3D-printed object ever – a human lung scaffold - which has demonstrated gas exchange in animal models

Category

3D-Bioprinting

Round

Seed

initial

July 2020

Notable Investors

*Based on gross estimated totalconsideration at time of transaction
×

Echo Laboratories

(Acquired by Cellinkfor $110M*)

Acquired by

Overview

Echo is a hybrid microscopy developer designed for biological research and pathologies. The company's products provide features such as inverted images, cell counting, phase contrast, bright field and fluorescence, enabling customers to have accurate images at a low cost.

Category

Life-Sciences Tools

Round

Seed, Bridge, Series A

initial

October 2016

Notable Investors

*Based on gross estimated totalconsideration at time of transaction
×

Circularis Biotechnologies

(Acquired by Ginkofor $56M*)

Acquired by

Overview

Using circular RNA, Circularis enables customers to optimize control of any gene in any species or any cell type. The company’s proprietary platform is the only technology for discovering, isolating, measuring, and enhancing all active promoters in a DNA sequence in a single reaction.

Category

RNA Platform

Round

Seed, Bridge

initial

August 2020

Notable Investors

*Based on gross estimated totalconsideration at time of transaction
×

Blue Mesa Health

(Acquired by Virgin Pulse for $6M*)

Acquired by

Overview

Developer of diabetes prevention digital platform designed to prevent or delay Type 2 Diabetes. The company's application offers wireless scale and activity tracker for monitoring progress, enabling users to lose approximately 5-7% of their body weight and reduce type2 diabetes risk by 58%.

Category

Digital Health

Round

Seed

initial

February 2018

Notable Investors

*Based on gross estimated totalconsideration at time of transaction
×

Notable Labs

(Acquired by Virgin Pulse for $6M*)

Acquired by

Overview

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment.

Category

Precision Oncology

Round

Seed, Series A, Series B, Series C

initial

October 2016

Notable Investors

*Based on gross estimated totalconsideration at time of transaction
×

CrowdMed

(Acquired by Virgin Pulse for $6M*)

Acquired by

Overview

Crowd Med is the developer of an online medical community platform intended to provide patients with a clear path towards their diagnosis and cure. The company's platform provides a collaborative approach for solving complex medical cases, enabling them to explore all possible medical diagnosis with reduced costs.

Category

Digital Health

Round

Seed

initial

February 2017

Notable Investors

*Based on gross estimated totalconsideration at time of transaction
×

Ligandal

(Acquired by Virgin Pulse for $6M*)

Acquired by

Overview

Ligandal develops nanomedicine therapies as gene editing tools with non-viral nano-carriers to treat gene-related diseases. Its therapies include peptide-based technologies for high-precision gene therapy, gene editing, regenerative medicine, immunotherapy, advanced antidote-vaccine technology genetic materials.

Category

Gene Therapy

Round

Seed, Bridge

initial

February 2017

Notable Investors

*Based on gross estimated totalconsideration at time of transaction
×

OccamzRazor

(Acquired by Virgin Pulse for $6M*)

Acquired by

Overview

OccamzRazor is an AI-driven neuroscience therapeutics platform for Parkinson's Disease. It analyzes a variety of biomedical data sets, constructing knowledge graph representing all known information about Parkinson's disease, enabling healthcare professionals to drive downstream therapeutic insight and strategic drug development.

Category

Computational Biology

Round

Seed

initial

October 2018

Notable Investors

*Based on gross estimated totalconsideration at time of transaction
×
Important Disclosures
Private Securities
Investments in private offerings are speculative and involve a high degree of risk. Investments in private offerings are not bank deposits and therefore are not insured by the FDIC or guaranteed by any other party. Investors must be qualified as an accredited investor to participate in private offerings and you may be required to verify your status as an accredited investor. No securities commission or regulatory authority has recommended or approved any investment or the accuracy or completeness of any of the information or materials provided by or through us.
Not Advice
This communication is not to be construed as investment, tax, or legal advice in relation to the relevant subject matter; investors must seek their own legal or other professional advice before making any investment to determine whether an investment is suitable for them.
Performance Not Guaranteed
Past performance is no guarantee of future results. Any historical returns, expected returns, or probability projections are not guaranteed and may not reflect actual future performance.
Risk of Loss
All investments involve a high degree of risk and may result in partial or total loss of your investment.
Liquidity Not Guaranteed
Investments offered by Bioverge are illiquid and there is never any guarantee that you will be able to exit your investments on the Secondary Market or at what price an exit (if any) will be achieved.
Not an Offer to Sell or Solicitation to Buy
The information presented on this Website does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities of Bioverge. Any such offer would only be made through of a prospectus, private placement memorandum, subscription agreement or similar documents. This Website is subject to material updating, revision and further amendment.
Conduct Your Own Due Diligence
This information is not intended to provide the sole basis for your evaluation of Bioverge. You should conduct your own due diligence of Bioverge and independently verify the information contained below before proceeding further with any investment in or other transaction with Bioverge. Our officers will make themselves available to answer any questions that you may have regarding our company, its business, operations and prospects should you decide to proceed further with an investment or other transaction with Bioverge.
Forward Looking Statements
The information set forth below includes statements, estimates, projections with respect to our anticipated future performance and other forward-looking statements, which are subject to risks, uncertainties and assumptions. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “future” or “continue”, the negative of these terms and other comparable terminology. Such forward-looking statements are based on current plans, estimates and expectations and are made pursuant to the Private Securities Litigation Reform Act of 1995. These statements, estimates and projections are based upon various assumptions that we made concerning our anticipated results and industry trends, which may or may not occur. We are not making any representations as to the accuracy of these statements, estimates or projections. Our actual performance may be materially different from the statements, estimates or projections set forth below. We are under no duty to update any of these forward-looking statements to conform them to actual results or revised expectations. Back